Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injection solution for subcutaneous use. It treats and helps prevent deep vein thrombosis and pulmonary embolism in patients undergoing surgery or with acute clotting events.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to prevent and treat venous thromboembolism.

- Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in patients undergoing abdominal or orthopedic surgery. - Acute deep vein thrombosis (DVT) treatment: facilitates clot resolution and reduces recurrence. - Pulmonary embolism (PE) treatment: provides anticoagulation to limit clot propagation in the lungs.

Tinzaparin sodium may be associated with a range of adverse reactions, most of which are related to its anticoagulant activity.

Common Side Effects: - Injection site reactions: erythema, pain or bruising at the subcutaneous site. - Bleeding: minor bruising or nosebleeds. - Elevated liver enzymes: transient increase in transaminases. - Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation. - Spinal/epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Allergic reactions: anaphylaxis or severe hypersensitivity.

When using Innohep, clinicians should consider several safety precautions to minimize risk.

- Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Concomitant anticoagulants: avoid simultaneous use with other anticoagulants or antiplatelet agents unless medically indicated. - Recent surgery or trauma: assess bleeding risk before initiating therapy. - Pregnancy: category B, use only if benefit outweighs potential risk. - Spinal/epidural procedures: postpone neuraxial anesthesia for at least 12 hours after the last dose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with several medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid): - Concurrent use with warfarin or direct oral anticoagulants: markedly increased bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin: additive antiplatelet effect leading to hemorrhage. - Thrombolytic agents (e.g., alteplase): synergistic anticoagulation may cause severe bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (clopidogrel, ticagrelor): monitor for signs of bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: may increase bleeding tendency. - ACE inhibitors or angiotensin receptor blockers: monitor renal function and platelet counts.